RT Journal Article
SR Electronic
T1 SIREN protocol: Impact of detectable anti-SARS-CoV-2 on the subsequent incidence of COVID-19 in 100,000 healthcare workers: do antibody positive healthcare workers have less reinfection than antibody negative healthcare workers?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.15.20247981
DO 10.1101/2020.12.15.20247981
A1 S. Wallace
A1 V. Hall
A1 A. Charlett
A1 P.D. Kirwan
A1 M.J. Cole
A1 M. Shrotri
A1 S. Rokadiya
A1 B. Oguti
A1 A. Vusirikala
A1 M. Zambon
A1 T. Brooks
A1 M. Ramsay
A1 C.S. Brown
A1 M.A. Chand
A1 S. Hopkins
YR 2020
UL http://medrxiv.org/content/early/2020/12/18/2020.12.15.20247981.abstract
AB Background The overall risk of reinfection in individuals who have previously had COVID-19 is unknown. To determine if prior SARS-CoV-2 infection (as determined by at least one positive commercial antibody test performed in a laboratory) in healthcare workers confers future immunity to reinfection, we are undertaking a large-scale prospective longitudinal cohort study of healthcare staff across the United Kingdom.Methods Population and Setting: staff members of healthcare organisations working in hospitals in the UKAt recruitment, participants will have their serum tested for anti-SARS-CoV-2 at baseline and using these results will be initially allocated to either antibody positive or antibody negative cohorts. Participants will undergo antibody and viral RNA testing at 1-4 weekly intervals throughout the study period, and based on these results may move between cohorts. Any results from testing undertaken for other reasons (e.g. symptoms, contact tracing etc.) or prior to study entry will also be included. Individuals will complete enrolment and fortnightly questionnaires on exposures and symptoms. Follow-up will be for at least 12 months from study entry.Outcome The primary outcome of interest is a reinfection with SARS -CoV-2 during the study period. Secondary outcomes will include incidence and prevalence (both RNA and antibody) of SARS-CoV-2, viral genomics, viral culture, symptom history and antibody/neutralising antibody titres.Conclusion This large study will help us to understand the impact of the presence of antibodies on the risk of reinfection with SARS-CoV-2; the results will have substantial implications in terms of national and international policy, as well as for risk management of contacts of COVID-19 cases.Trial Registration IRAS ID 284460, HRA and Health and Care Research Wales approval granted 22 May 2020.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIRAS ID 284460Funding StatementThe study is funded by the Department of Health and Social Care and Public Health England, with contributions from the Scottish, Welsh and Northern Irish governments.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Berkshire Research Ethnics Committee Approval by HRA and Health and Care Research WalesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable